Overcome Translational & Clinical Challenges to Develop More Effective & Disease-Modifying IPF Drugs
Accelerate the Development of More Meaningful & Disease-Limiting Therapeutics for IPF Patients
The only and most comprehensive forum exclusively addressing the translational and clinical challenges limiting the idiopathic pulmonary fibrosis industry from transforming patient’s lives with more effective and meaningful drug development… is back!
Gathering cross-industry experts alongside pioneering academia once again, the 4th IPF Summit is the must-attend forum for IPF drug sponsors and those strategically assessing anti-fibrotic drug development for archetypal fibrotic diseases. Evolve your combination strategy for NASH, PF-ILD or wider pathological fibrosis by learning from the industry’s best in a collaborative, dynamic and instructive setting.
From the latest interrogation of pathophysiology, genetics and drug mechanisms through to constructively outlining the lumping versus splitting debate, join over 150 respiratory and fibrosis stakeholders at this unique and unrivaled conference, as together they pre-competitively advance the IPF drug development frontier.
“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!”
IPF Attendee, Ceders-Sinai Medical Center
“This was the best pragmatic development conference for pulmonary fibrosis that I have been too.”
- IPF Attendee, Biogen
“I thought this disease-specific conference was informative, by planning a concentrated topic it gave an opportunity to look through a tighter lens."
- IPF Attendee, Genentech
“Very well organized and informative, bringing together some very experienced professionals in the IPF world.”
- IPF Attendee, Mayo Clinic
Expert Speakers for 2020 Include:
Director, Clinical Development, ILD Therapeutic Area, Boehringer Ingelheim & Adjunct Professor
University of Michigan
Chief Division of Pulmonary & Critical Care Medicine
Weill Cornell Medicine
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Yale School of Medicine
Director of Interstitial Lung Disease Program